bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S1 from Sarcoma Cells Secrete Hypoxia-Modified Collagen VI to Weaken the Lung Endothelial Barrier and Promote Metastasis
Authors: Liu Ying , Murazzi Ileana , Fuller Ashley M. , Pan Hehai , Irizarry-Negron Valerie M. , Devine Ann , Katti Rohan , Skuli Nicolas , Ciotti Gabrielle E. , Pak Koreana , Pack Michael A. , Simon M. Celeste , Weber Kristy , Cooper Kumarasen , Eisinger-Mathason T.S. Karin
Published: April 2024

Phospho Antibody Array Data
Supplemental Figure S8 from Subclonal Cancer Driver Mutations Are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas
Authors: Underhill Hunter R. , Karsy Michael , Davidson Christian J. , Hellwig Sabine , Stevenson Samuel , Goold Eric A. , Vincenti Sydney , Sellers Drew L. , Dean Charlie , Harrison Brion E. , Bronner Mary P. , Colman Howard , Jensen Randy L.
Published: April 2024

Supplemental Figure S8. Alternative experimental and in vitro noise reduction strategies without substantive improvement in error.
Supplemental Figure S7 from Subclonal Cancer Driver Mutations Are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas
Authors: Underhill Hunter R. , Karsy Michael , Davidson Christian J. , Hellwig Sabine , Stevenson Samuel , Goold Eric A. , Vincenti Sydney , Sellers Drew L. , Dean Charlie , Harrison Brion E. , Bronner Mary P. , Colman Howard , Jensen Randy L.
Published: April 2024

Supplemental Figure S7. True2 reduces false positives across all variant allele frequency (VAF) categories.
Supplemental Figure S5 from Subclonal Cancer Driver Mutations Are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas
Authors: Underhill Hunter R. , Karsy Michael , Davidson Christian J. , Hellwig Sabine , Stevenson Samuel , Goold Eric A. , Vincenti Sydney , Sellers Drew L. , Dean Charlie , Harrison Brion E. , Bronner Mary P. , Colman Howard , Jensen Randy L.
Published: April 2024

Supplemental Figure S5. Effect of using the dbSNP database to remove potential contamination.
Supplemental Figure S2 from Subclonal Cancer Driver Mutations Are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas
Authors: Underhill Hunter R. , Karsy Michael , Davidson Christian J. , Hellwig Sabine , Stevenson Samuel , Goold Eric A. , Vincenti Sydney , Sellers Drew L. , Dean Charlie , Harrison Brion E. , Bronner Mary P. , Colman Howard , Jensen Randy L.
Published: April 2024

Supplemental Figure S2. Preconsensus metrics of sequencing data.
Supplemental Figure S15 from Subclonal Cancer Driver Mutations Are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas
Authors: Underhill Hunter R. , Karsy Michael , Davidson Christian J. , Hellwig Sabine , Stevenson Samuel , Goold Eric A. , Vincenti Sydney , Sellers Drew L. , Dean Charlie , Harrison Brion E. , Bronner Mary P. , Colman Howard , Jensen Randy L.
Published: April 2024

Supplemental Figure S15. Distribution of allele frequencies for somatic mutations discovered by True2 in tumor and peritumoral edema of adult diffuse gliomas.
Supplement 6 from Subclonal Cancer Driver Mutations Are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas
Authors: Underhill Hunter R. , Karsy Michael , Davidson Christian J. , Hellwig Sabine , Stevenson Samuel , Goold Eric A. , Vincenti Sydney , Sellers Drew L. , Dean Charlie , Harrison Brion E. , Bronner Mary P. , Colman Howard , Jensen Randy L.
Published: April 2024

Data used to construct figures.
Supplement 1 from Subclonal Cancer Driver Mutations Are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas
Authors: Underhill Hunter R. , Karsy Michael , Davidson Christian J. , Hellwig Sabine , Stevenson Samuel , Goold Eric A. , Vincenti Sydney , Sellers Drew L. , Dean Charlie , Harrison Brion E. , Bronner Mary P. , Colman Howard , Jensen Randy L.
Published: April 2024

BED file of custom-designed panel used during analysis.
Supplementary Movie legends from Human Tumor–Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal Trogocytosis
Authors: Singhal Sunil , Rao Abhishek S. , Stadanlick Jason , Bruns Kyle , Sullivan Neil T. , Bermudez Andres , Honig-Frand Adam , Krouse Ryan , Arambepola Sachinthani , Guo Emily , Moon Edmund K. , Georgiou George , Valerius Thomas , Albelda Steven M. , Eruslanov Evgeniy B.
Published: April 2024

Supplementary Movie S1. TAM-mediated phagocytosis of rituximab-opsonized Daudi tumor cells. PKH26-labeled TAM (red) were incubated with PKH67-labeled Daudi tumor cells (green) at a 3:1 E:T ratio for 2 hrs in the presence of rituximab (1ug/ml). Time-lapse microscopy was performed using a Leica DMI4000 inverted microscope. The images were taken every 5 min with Hamamatsu ImagEM 16-bit cooled EMCCD camera at 20x magnification.
Supplementary Movie S2. TAM-mediated trogocytosis of cetuximab-opsonized A431 tumor cells. PKH26-labeled TAM (red) were incubated with PKH67-labeled A431 tumor cells (green) at a 3:1 E:T ratio for 2 hrs in the presence of cetuximab (1ug/ml). Time-lapse microscopy was performed using a Leica DMI4000 inverted microscope. The images were taken every 5 min with Hamamatsu ImagEM 16-bit cooled EMCCD camera at 20x magnification.
Supplementary Movie S3. Sublethal trogocytosis performed by PBN during their interaction with cetuximab–opsonized A431 tumor cells. PKH26-labeled PBN (red) were incubated with PKH67-labeled A431 targets (green) at a 10:1 E:T ratio for 2 hrs in the presence of cetuximab (1ug/ml). Time-lapse microscopy was performed using a Leica DMI4000 inverted microscope. The images were taken every 5 min with Hamamatsu ImagEM 16-bit cooled EMCCD camera at 20x magnification.
Supplementary Movie S4. Lethal trogocytosis performed by blood monocytes during their interaction with cetuximab–opsonized A431 tumor cells. PKH26-labeled monocytes (red) were incubated with PKH67-labeled A431 targets (green) at a 10:1 E:T ratio for 2 hrs in the presence of cetuximab (1ug/ml). Time-lapse microscopy was performed using a Leica DMI4000 inverted microscope. The images were taken every 5 min with Hamamatsu ImagEM 16-bit cooled EMCCD camera at 20x magnification.
Supplementary Figure S9 from Human Tumor–Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal Trogocytosis
Authors: Singhal Sunil , Rao Abhishek S. , Stadanlick Jason , Bruns Kyle , Sullivan Neil T. , Bermudez Andres , Honig-Frand Adam , Krouse Ryan , Arambepola Sachinthani , Guo Emily , Moon Edmund K. , Georgiou George , Valerius Thomas , Albelda Steven M. , Eruslanov Evgeniy B.
Published: April 2024

Supplementary Figure S9. (A and B) Representative dotplots and summary results showing the ability of TAM pretreated with blocking anti-CD64 F(ab')2 and anti-CD32 F(ab')2 fragments (5ug/ml) to kill PKH67+ A431 cells at a 1:1 E:T ratio in the presence of cetuximab (1ug/ml) in a 12 hrs FACS-based assay. Dead A431 tumor cells were defined as TO-PRO-3+PKH67+ cells. (C and D) Representative dotplots and summary results demonstrating the ability of HLA-A2neg TAM to stimulate of Ly95 cells responses (intracellular IFN-γ) after their preincubation with cetuximab-opsonized A549/HLA-A2+NY-ESO tumor cells at the indicated time points. Kruskal-Wallis multiple comparisons test. Data represented as mean ± SEM. (E) The expression of NY-ESO-1 protein in different batches of transduced A549 tumor cells. The expression of intracellular NY-ESO was evaluated by flow cytometry using NY-ESO-1 mAb (clone D1Q2U) that recognizes endogenous levels of total NY-ESO-1 protein. Non transduced A549 cells were used as a control. (F-H) Representative dotplots and cumulative data showing the ability of HLA-A2+TAM to stimulate of Ly95 cells responses (intracellular IFN-γ) after preincubation with A549/HLA-A2+NY-ESOhi (F) and A549/HLA-A2+NY-ESOlo tumor cells (G) in the presence or absence of cetuximab for 4 hrs. Wilcoxon matched pairs test for groups with (+) or without (-) Ab. * p<0,01. Kruskal-Wallis test for TAM groups co-cultured with A549/HLA-A2+NY-ESOhi or A549/HLA-A2+NY-ESOlo. Data represented as mean ± SEM. FcR+ effectors were freshly isolated for all experiments.
Supplementary Figure S3 from Human Tumor–Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal Trogocytosis
Authors: Singhal Sunil , Rao Abhishek S. , Stadanlick Jason , Bruns Kyle , Sullivan Neil T. , Bermudez Andres , Honig-Frand Adam , Krouse Ryan , Arambepola Sachinthani , Guo Emily , Moon Edmund K. , Georgiou George , Valerius Thomas , Albelda Steven M. , Eruslanov Evgeniy B.
Published: April 2024

Supplementary Figure S3. The correlation analyses between the ability of blood and tumor FcR+ myeloid effectors to regulate A431 tumor cell growth in the presence of anti-EGFR Abs and the expression of indicated FcR on the surface of these effectors. The effect of FcR+ effectors on A431 tumor cell growth was evaluated in IncuCyte® Live Cell Analysis System. The expression of FcR was analyzed in a single-cell suspension obtained from digested tumors by flow cytometry. Spearman test. Number of patients included in each analysis is indicated on the graphs
Supplementary data from Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
Authors: Chaudhri Apoorvi , Lizee Gregory , Hwu Patrick , Rai Kunal
Published: April 2024

Supplementary data
Supplementary Table S1 from PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer
Authors: Yamamoto Takehiro , Hayashida Tetsu , Masugi Yohei , Oshikawa Kiyotaka , Hayakawa Noriyo , Itoh Mai , Nishime Chiyoko , Suzuki Masami , Nagayama Aiko , Kawai Yuko , Hishiki Takako , Matsuura Tomomi , Naito Yoshiko , Kubo Akiko , Yamamoto Arisa , Yoshioka Yujiro , Kurahori Tomokazu , Nagasaka Misa , Takizawa Minako , Takano Naoharu , Kawakami Koji , Sakamoto Michiie , Wakui Masatoshi , Yamamoto Takushi , Kitagawa Yuko , Kabe Yasuaki , Horisawa Kenichi , Suzuki Atsushi , Matsumoto Masaki , Suematsu Makoto
Published: April 2024

Table S1
Supplementary Fig.S6 from PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer
Authors: Yamamoto Takehiro , Hayashida Tetsu , Masugi Yohei , Oshikawa Kiyotaka , Hayakawa Noriyo , Itoh Mai , Nishime Chiyoko , Suzuki Masami , Nagayama Aiko , Kawai Yuko , Hishiki Takako , Matsuura Tomomi , Naito Yoshiko , Kubo Akiko , Yamamoto Arisa , Yoshioka Yujiro , Kurahori Tomokazu , Nagasaka Misa , Takizawa Minako , Takano Naoharu , Kawakami Koji , Sakamoto Michiie , Wakui Masatoshi , Yamamoto Takushi , Kitagawa Yuko , Kabe Yasuaki , Horisawa Kenichi , Suzuki Atsushi , Matsumoto Masaki , Suematsu Makoto
Published: April 2024

Fig.S6
Supplementary Fig.S4 from PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer
Authors: Yamamoto Takehiro , Hayashida Tetsu , Masugi Yohei , Oshikawa Kiyotaka , Hayakawa Noriyo , Itoh Mai , Nishime Chiyoko , Suzuki Masami , Nagayama Aiko , Kawai Yuko , Hishiki Takako , Matsuura Tomomi , Naito Yoshiko , Kubo Akiko , Yamamoto Arisa , Yoshioka Yujiro , Kurahori Tomokazu , Nagasaka Misa , Takizawa Minako , Takano Naoharu , Kawakami Koji , Sakamoto Michiie , Wakui Masatoshi , Yamamoto Takushi , Kitagawa Yuko , Kabe Yasuaki , Horisawa Kenichi , Suzuki Atsushi , Matsumoto Masaki , Suematsu Makoto
Published: April 2024

Fig.S4
Table S2 from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia
Authors: Su Yongwei , Carter Jenna L. , Li Xinyu , Fukuda Yu , Gray Ashley , Lynch John , Edwards Holly , Ma Jun , Schreiner Patrick , Polin Lisa , Kushner Juiwanna , Dzinic Sijana H. , Buck Steven A. , Pruett-Miller Shondra M. , Hege-Hurrish Katie , Robinson Camenzind , Qiao Xinan , Liu Shuang , Wu Shuangshuang , Wang Guan , Li Jing , Allen Joshua E. , Prabhu Varun V. , Schimmer Aaron D. , Joshi Dhananjay , Kalhor-Monfared Shiva , Watson Iain D. G. , Marcellus Richard , Isaac Methvin B. , Al-awar Rima , Taub Jeffrey W. , Lin Hai , Schuetz John D. , Ge Yubin
Published: April 2024

Patient characteristics for AML cell lines
Supplementary Fig.S2 from PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer
Authors: Yamamoto Takehiro , Hayashida Tetsu , Masugi Yohei , Oshikawa Kiyotaka , Hayakawa Noriyo , Itoh Mai , Nishime Chiyoko , Suzuki Masami , Nagayama Aiko , Kawai Yuko , Hishiki Takako , Matsuura Tomomi , Naito Yoshiko , Kubo Akiko , Yamamoto Arisa , Yoshioka Yujiro , Kurahori Tomokazu , Nagasaka Misa , Takizawa Minako , Takano Naoharu , Kawakami Koji , Sakamoto Michiie , Wakui Masatoshi , Yamamoto Takushi , Kitagawa Yuko , Kabe Yasuaki , Horisawa Kenichi , Suzuki Atsushi , Matsumoto Masaki , Suematsu Makoto
Published: April 2024

Fig.S2
Supplementary Data - MV4-11 metabolomics from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia
Authors: Su Yongwei , Carter Jenna L. , Li Xinyu , Fukuda Yu , Gray Ashley , Lynch John , Edwards Holly , Ma Jun , Schreiner Patrick , Polin Lisa , Kushner Juiwanna , Dzinic Sijana H. , Buck Steven A. , Pruett-Miller Shondra M. , Hege-Hurrish Katie , Robinson Camenzind , Qiao Xinan , Liu Shuang , Wu Shuangshuang , Wang Guan , Li Jing , Allen Joshua E. , Prabhu Varun V. , Schimmer Aaron D. , Joshi Dhananjay , Kalhor-Monfared Shiva , Watson Iain D. G. , Marcellus Richard , Isaac Methvin B. , Al-awar Rima , Taub Jeffrey W. , Lin Hai , Schuetz John D. , Ge Yubin
Published: April 2024

MV4-11 metabolomics data
Figure S7 from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia
Authors: Su Yongwei , Carter Jenna L. , Li Xinyu , Fukuda Yu , Gray Ashley , Lynch John , Edwards Holly , Ma Jun , Schreiner Patrick , Polin Lisa , Kushner Juiwanna , Dzinic Sijana H. , Buck Steven A. , Pruett-Miller Shondra M. , Hege-Hurrish Katie , Robinson Camenzind , Qiao Xinan , Liu Shuang , Wu Shuangshuang , Wang Guan , Li Jing , Allen Joshua E. , Prabhu Varun V. , Schimmer Aaron D. , Joshi Dhananjay , Kalhor-Monfared Shiva , Watson Iain D. G. , Marcellus Richard , Isaac Methvin B. , Al-awar Rima , Taub Jeffrey W. , Lin Hai , Schuetz John D. , Ge Yubin
Published: April 2024

Supplementary Figure S7
Supplementary Fig.S15 from PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer
Authors: Yamamoto Takehiro , Hayashida Tetsu , Masugi Yohei , Oshikawa Kiyotaka , Hayakawa Noriyo , Itoh Mai , Nishime Chiyoko , Suzuki Masami , Nagayama Aiko , Kawai Yuko , Hishiki Takako , Matsuura Tomomi , Naito Yoshiko , Kubo Akiko , Yamamoto Arisa , Yoshioka Yujiro , Kurahori Tomokazu , Nagasaka Misa , Takizawa Minako , Takano Naoharu , Kawakami Koji , Sakamoto Michiie , Wakui Masatoshi , Yamamoto Takushi , Kitagawa Yuko , Kabe Yasuaki , Horisawa Kenichi , Suzuki Atsushi , Matsumoto Masaki , Suematsu Makoto
Published: April 2024

Fig.S15
Figure S5 from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia
Authors: Su Yongwei , Carter Jenna L. , Li Xinyu , Fukuda Yu , Gray Ashley , Lynch John , Edwards Holly , Ma Jun , Schreiner Patrick , Polin Lisa , Kushner Juiwanna , Dzinic Sijana H. , Buck Steven A. , Pruett-Miller Shondra M. , Hege-Hurrish Katie , Robinson Camenzind , Qiao Xinan , Liu Shuang , Wu Shuangshuang , Wang Guan , Li Jing , Allen Joshua E. , Prabhu Varun V. , Schimmer Aaron D. , Joshi Dhananjay , Kalhor-Monfared Shiva , Watson Iain D. G. , Marcellus Richard , Isaac Methvin B. , Al-awar Rima , Taub Jeffrey W. , Lin Hai , Schuetz John D. , Ge Yubin
Published: April 2024

Supplementary Figure S5
Figure S3 from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia
Authors: Su Yongwei , Carter Jenna L. , Li Xinyu , Fukuda Yu , Gray Ashley , Lynch John , Edwards Holly , Ma Jun , Schreiner Patrick , Polin Lisa , Kushner Juiwanna , Dzinic Sijana H. , Buck Steven A. , Pruett-Miller Shondra M. , Hege-Hurrish Katie , Robinson Camenzind , Qiao Xinan , Liu Shuang , Wu Shuangshuang , Wang Guan , Li Jing , Allen Joshua E. , Prabhu Varun V. , Schimmer Aaron D. , Joshi Dhananjay , Kalhor-Monfared Shiva , Watson Iain D. G. , Marcellus Richard , Isaac Methvin B. , Al-awar Rima , Taub Jeffrey W. , Lin Hai , Schuetz John D. , Ge Yubin
Published: April 2024

Supplementary Figure S3
STable 1 from Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
Authors: Raucci Franca , Vernieri Claudio , Di Tano Maira , Ligorio Francesca , Blaževitš Olga , Lazzeri Samuel , Shmahala Anastasiya , Fragale Giuseppe , Salvadori Giulia , Varano Gabriele , Casola Stefano , Buono Roberta , Visco Euplio , de Braud Filippo , Longo Valter D.
Published: April 2024

Supplementary Data - Table 1
SFigure5 from Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
Authors: Raucci Franca , Vernieri Claudio , Di Tano Maira , Ligorio Francesca , Blaževitš Olga , Lazzeri Samuel , Shmahala Anastasiya , Fragale Giuseppe , Salvadori Giulia , Varano Gabriele , Casola Stefano , Buono Roberta , Visco Euplio , de Braud Filippo , Longo Valter D.
Published: April 2024

SFigure5
SFigure4 from Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
Authors: Raucci Franca , Vernieri Claudio , Di Tano Maira , Ligorio Francesca , Blaževitš Olga , Lazzeri Samuel , Shmahala Anastasiya , Fragale Giuseppe , Salvadori Giulia , Varano Gabriele , Casola Stefano , Buono Roberta , Visco Euplio , de Braud Filippo , Longo Valter D.
Published: April 2024

SFigure4
SFigure3 from Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
Authors: Raucci Franca , Vernieri Claudio , Di Tano Maira , Ligorio Francesca , Blaževitš Olga , Lazzeri Samuel , Shmahala Anastasiya , Fragale Giuseppe , Salvadori Giulia , Varano Gabriele , Casola Stefano , Buono Roberta , Visco Euplio , de Braud Filippo , Longo Valter D.
Published: April 2024

SFigure3
Table S1C from Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche
Authors: Xu Yanyang , Deng Chuangzhong , Chen Hongmin , Song YiJiang , Xu Huaiyuan , Song Guohui , Wang Xinliang , Luo Tianqi , Chen Weiqing , Ma Jiahui , Zeng Anyu , Huang Shujing , Chen Zhihao , Fu Jianchang , Gong Ming , Tai Yi , Huang Anfei , Feng Huixiong , Hu Jinxin , Zhu Xiaojun , Tang Qinglian , Lu Jinchang , Wang Jin
Published: April 2024

List of RT-qPCR primers used in this study.
Figure S9 from Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche
Authors: Xu Yanyang , Deng Chuangzhong , Chen Hongmin , Song YiJiang , Xu Huaiyuan , Song Guohui , Wang Xinliang , Luo Tianqi , Chen Weiqing , Ma Jiahui , Zeng Anyu , Huang Shujing , Chen Zhihao , Fu Jianchang , Gong Ming , Tai Yi , Huang Anfei , Feng Huixiong , Hu Jinxin , Zhu Xiaojun , Tang Qinglian , Lu Jinchang , Wang Jin
Published: April 2024

Abrogating the CXCL14-ITGα11β1 axis interrupts matrix remodeling of MAFs and fibrogenic reprogramming.
Figure S5 from Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche
Authors: Xu Yanyang , Deng Chuangzhong , Chen Hongmin , Song YiJiang , Xu Huaiyuan , Song Guohui , Wang Xinliang , Luo Tianqi , Chen Weiqing , Ma Jiahui , Zeng Anyu , Huang Shujing , Chen Zhihao , Fu Jianchang , Gong Ming , Tai Yi , Huang Anfei , Feng Huixiong , Hu Jinxin , Zhu Xiaojun , Tang Qinglian , Lu Jinchang , Wang Jin
Published: April 2024

CXCL14 induces fibrogenic reprogramming in fibroblastic and osteosarcoma cells.
Figure S10 from Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche
Authors: Xu Yanyang , Deng Chuangzhong , Chen Hongmin , Song YiJiang , Xu Huaiyuan , Song Guohui , Wang Xinliang , Luo Tianqi , Chen Weiqing , Ma Jiahui , Zeng Anyu , Huang Shujing , Chen Zhihao , Fu Jianchang , Gong Ming , Tai Yi , Huang Anfei , Feng Huixiong , Hu Jinxin , Zhu Xiaojun , Tang Qinglian , Lu Jinchang , Wang Jin
Published: April 2024

ITGα11β1+ fibroblast infiltration is correlated with OSA metastasis.
Figure S1 from Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche
Authors: Xu Yanyang , Deng Chuangzhong , Chen Hongmin , Song YiJiang , Xu Huaiyuan , Song Guohui , Wang Xinliang , Luo Tianqi , Chen Weiqing , Ma Jiahui , Zeng Anyu , Huang Shujing , Chen Zhihao , Fu Jianchang , Gong Ming , Tai Yi , Huang Anfei , Feng Huixiong , Hu Jinxin , Zhu Xiaojun , Tang Qinglian , Lu Jinchang , Wang Jin
Published: April 2024

Single-cell transcriptomic sequencing analyzed the heterogeneity of intratumoral malignant subclusters in osteosarcoma.
Table S2 from Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia
Authors: Monteith Andrew J. , Ramsey Haley E. , Silver Alexander J. , Brown Donovan , Greenwood Dalton , Smith Brianna N. , Wise Ashley D. , Liu Juan , Olmstead Sarah D. , Watke Jackson , Arrate Maria P. , Gorska Agnieszka E. , Fuller Londa , Locasale Jason W. , Stubbs Matthew C. , Rathmell Jeffrey C. , Savona Michael R.
Published: April 2024

Table S2: Characteristics of AML patient samples tested with BETi.
Figure S4 from Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia
Authors: Monteith Andrew J. , Ramsey Haley E. , Silver Alexander J. , Brown Donovan , Greenwood Dalton , Smith Brianna N. , Wise Ashley D. , Liu Juan , Olmstead Sarah D. , Watke Jackson , Arrate Maria P. , Gorska Agnieszka E. , Fuller Londa , Locasale Jason W. , Stubbs Matthew C. , Rathmell Jeffrey C. , Savona Michael R.
Published: April 2024

Figure S4: UK5099 does not enhance the efficacy of BETi in preventing MOLM-13 chimerism. NSGS mice were engrafted with MOLM-13 cells and treated with vehicle control, BETi (50 mg/kg) 5 times a week, twice daily and/or UK5099 (40 mg/kg) three times a week, once daily. After 2 wks, peripheral blood (BL), spleen (SPL), and bone marrow (BM) were harvested for chimerism analysis. Each point represents a single mouse (n = 5). Two-way ANOVA with Tukey multiple comparisons test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, ns = not significant).
Figure S1 from Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia
Authors: Monteith Andrew J. , Ramsey Haley E. , Silver Alexander J. , Brown Donovan , Greenwood Dalton , Smith Brianna N. , Wise Ashley D. , Liu Juan , Olmstead Sarah D. , Watke Jackson , Arrate Maria P. , Gorska Agnieszka E. , Fuller Londa , Locasale Jason W. , Stubbs Matthew C. , Rathmell Jeffrey C. , Savona Michael R.
Published: April 2024

Figure S1: Glutaminolysis and fatty acid oxidation does not allow MOLM-13 to metabolically bypass BET inhibition. (A) MV-4-11 and MOLM-13 cells were cultured for 72 hr with BETi (0.15 µM) and viability quantified using a fluorescent plate reader. Viability was quantified relative to cells treated with vehicle control. Each point represents the mean (technical triplicate) value obtained from cells from an individual experiment (n=3). (B-E) MV-4-11 and MOLM-13 cells were loaded with a CellTrace dye and cultured for 72 hr with BETi and either (B-C) V-0302 (25 µM) or (D-E) etomoxir (150 µM). (B, D) To assess replication, CellTrace fluorescence intensity was quantified by flow cytometry and (C, E) viability was quantified in a fluorescent plate reader. Replication and viability were quantified relative to cells treated with vehicle control. (F) Raw CT values from qPCR experiment in Fig. 2A. Each point represents (B, D) the median fluorescent intensity (MFI) from or (C, E) the mean (technical triplicate) value obtained from cells from an individual experiment (n=3). (A) Paired t test or (B-E) Two-way ANOVA with Sidak’s multiple comparisons test (**P ≤ 0.01, ns = not significant).
Table S5 from Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development
Authors: Goldberg Lior , Haas Eric R. , Urak Ryan , Vyas Vibhuti , Pathak Khyatiben V. , Garcia-Mansfield Krystine , Pirrotte Patrick , Singhal Jyotsana , Figarola James L. , Aldoss Ibrahim , Forman Stephen J. , Wang Xiuli
Published: April 2024

Supplementary Table 5: A mass cytometry integrative panel with antibodies specific for CAR, cell lineage, tissue residence, differentiation, effector, and immune checkpoint proteins involved in CAR T cell function.
Table S4 from Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development
Authors: Goldberg Lior , Haas Eric R. , Urak Ryan , Vyas Vibhuti , Pathak Khyatiben V. , Garcia-Mansfield Krystine , Pirrotte Patrick , Singhal Jyotsana , Figarola James L. , Aldoss Ibrahim , Forman Stephen J. , Wang Xiuli
Published: April 2024

Supplementary Table 4: Metabolomics analysis of patients’ day 28 CSF and CSF from pooled donors.
Table S3 from Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development
Authors: Goldberg Lior , Haas Eric R. , Urak Ryan , Vyas Vibhuti , Pathak Khyatiben V. , Garcia-Mansfield Krystine , Pirrotte Patrick , Singhal Jyotsana , Figarola James L. , Aldoss Ibrahim , Forman Stephen J. , Wang Xiuli
Published: April 2024

Supplementary Table 3: Metabolomics analysis of patients’ matched CSF and PB samples on day 28 post-infusion.
Supplementary Table from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Authors: Lumeau Audrey , Bery Nicolas , Francès Audrey , Gayral Marion , Labrousse Guillaume , Ribeyre Cyril , Lopez Charlene , Nevot Adele , El Kaoutari Abdessamad , Hanoun Naima , Sarot Emeline , Perrier Marion , Pont Frederic , Cerapio Juan-Pablo , Fournié Jean-Jacques , Lopez Frederic , Madrid-Mencia Miguel , Pancaldi Vera , Pillaire Marie-Jeanne , Bergoglio Valerie , Torrisani Jerome , Dusetti Nelson , Hoffmann Jean-Sebastien , Buscail Louis , Lutzmann Malik , Cordelier Pierre
Published: April 2024

Supplemetary table
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Authors: Lumeau Audrey , Bery Nicolas , Francès Audrey , Gayral Marion , Labrousse Guillaume , Ribeyre Cyril , Lopez Charlene , Nevot Adele , El Kaoutari Abdessamad , Hanoun Naima , Sarot Emeline , Perrier Marion , Pont Frederic , Cerapio Juan-Pablo , Fournié Jean-Jacques , Lopez Frederic , Madrid-Mencia Miguel , Pancaldi Vera , Pillaire Marie-Jeanne , Bergoglio Valerie , Torrisani Jerome , Dusetti Nelson , Hoffmann Jean-Sebastien , Buscail Louis , Lutzmann Malik , Cordelier Pierre
Published: April 2024

Figure S6
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Authors: Lumeau Audrey , Bery Nicolas , Francès Audrey , Gayral Marion , Labrousse Guillaume , Ribeyre Cyril , Lopez Charlene , Nevot Adele , El Kaoutari Abdessamad , Hanoun Naima , Sarot Emeline , Perrier Marion , Pont Frederic , Cerapio Juan-Pablo , Fournié Jean-Jacques , Lopez Frederic , Madrid-Mencia Miguel , Pancaldi Vera , Pillaire Marie-Jeanne , Bergoglio Valerie , Torrisani Jerome , Dusetti Nelson , Hoffmann Jean-Sebastien , Buscail Louis , Lutzmann Malik , Cordelier Pierre
Published: April 2024

Figure S4
Data from Sarcoma Cells Secrete Hypoxia-Modified Collagen VI to Weaken the Lung Endothelial Barrier and Promote Metastasis
Authors: Liu Ying , Murazzi Ileana , Fuller Ashley M. , Pan Hehai , Irizarry-Negron Valerie M. , Devine Ann , Katti Rohan , Skuli Nicolas , Ciotti Gabrielle E. , Pak Koreana , Pack Michael A. , Simon M. Celeste , Weber Kristy , Cooper Kumarasen , Eisinger-Mathason T.S. Karin
Published: April 2024

Abstract
Intratumoral hypoxia correlates with metastasis and poor survival in patients with sarcoma. Using an impedance sensing assay and a zebrafish intravital microinjection model, we demonstrated here that the hypoxia-inducible collagen-modifying enzyme lysyl hydroxylase PLOD2 and its substrate collagen type VI (COLVI) weaken the lung endothelial barrier and promote transendothelial migration. Mechanistically, hypoxia-induced PLOD2 in sarcoma cells modified COLVI, which was then secreted into the vasculature. Upon reaching the apical surface of lung endothelial cells, modified COLVI from tumor cells activated integrin β1 (ITGβ1). Furthermore, activated ITGβ1 colocalized with Kindlin2, initiating their interaction with F-actin and prompting its polymerization. Polymerized F-actin disrupted endothelial adherens junctions and induced barrier dysfunction. Consistently, modified and secreted COLVI was required for the late stages of lung metastasis in vivo. Analysis of patient gene expression and survival data from The Cancer Genome Atlas (TCGA) revealed an association between the expression of both PLOD2 and COLVI and patient survival. Furthermore, high levels of COLVI were detected in surgically resected sarcoma metastases from patient lungs and in the blood of tumor-bearing mice. Together, these data identify a mechanism of sarcoma lung metastasis, revealing opportunities for therapeutic intervention.
Significance:
Collagen type VI modified by hypoxia-induced PLOD2 is secreted by sarcoma cells and binds to integrin β1 on endothelial cells to induce barrier dysfunction, which promotes sarcoma vascular dissemination and metastasis.
Data from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia
Authors: Su Yongwei , Carter Jenna L. , Li Xinyu , Fukuda Yu , Gray Ashley , Lynch John , Edwards Holly , Ma Jun , Schreiner Patrick , Polin Lisa , Kushner Juiwanna , Dzinic Sijana H. , Buck Steven A. , Pruett-Miller Shondra M. , Hege-Hurrish Katie , Robinson Camenzind , Qiao Xinan , Liu Shuang , Wu Shuangshuang , Wang Guan , Li Jing , Allen Joshua E. , Prabhu Varun V. , Schimmer Aaron D. , Joshi Dhananjay , Kalhor-Monfared Shiva , Watson Iain D. G. , Marcellus Richard , Isaac Methvin B. , Al-awar Rima , Taub Jeffrey W. , Lin Hai , Schuetz John D. , Ge Yubin
Published: April 2024

Abstract
Eradication of acute myeloid leukemia (AML) is therapeutically challenging; many patients succumb to AML despite initially responding to conventional treatments. Here, we showed that the imipridone ONC213 elicits potent antileukemia activity in a subset of AML cell lines and primary patient samples, particularly in leukemia stem cells, while producing negligible toxicity in normal hematopoietic cells. ONC213 suppressed mitochondrial respiration and elevated α-ketoglutarate by suppressing α-ketoglutarate dehydrogenase (αKGDH) activity. Deletion of OGDH, which encodes αKGDH, suppressed AML fitness and impaired oxidative phosphorylation, highlighting the key role for αKGDH inhibition in ONC213-induced death. ONC213 treatment induced a unique mitochondrial stress response and suppressed de novo protein synthesis in AML cells. Additionally, ONC213 reduced the translation of MCL1, which contributed to ONC213-induced apoptosis. Importantly, a patient-derived xenograft from a relapsed AML patient was sensitive to ONC213 in vivo. Collectively, these findings support further development of ONC213 for treating AML.
Significance:
In AML cells, ONC213 suppresses αKGDH, which induces a unique mitochondrial stress response, and reduces MCL1 to decrease oxidative phosphorylation and elicit potent antileukemia activity.

See related commentary by Boët and Sarry, p. 950
Data from Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche
Authors: Xu Yanyang , Deng Chuangzhong , Chen Hongmin , Song YiJiang , Xu Huaiyuan , Song Guohui , Wang Xinliang , Luo Tianqi , Chen Weiqing , Ma Jiahui , Zeng Anyu , Huang Shujing , Chen Zhihao , Fu Jianchang , Gong Ming , Tai Yi , Huang Anfei , Feng Huixiong , Hu Jinxin , Zhu Xiaojun , Tang Qinglian , Lu Jinchang , Wang Jin
Published: April 2024

Abstract
Cooperation between primary malignant cells and stromal cells can mediate the establishment of lung metastatic niches. Here, we characterized the landscape of cell populations in the tumor microenvironment in treatment-naïve osteosarcoma using single-cell RNA sequencing and identified a stem cell–like cluster with tumor cell–initiating properties and prometastatic traits. CXCL14 was specifically enriched in the stem cell–like cluster and was also significantly upregulated in lung metastases compared with primary tumors. CXCL14 induced stromal reprogramming and evoked a malignant phenotype in fibroblasts to form a supportive lung metastatic niche. Binding of CXCL14 to heterodimeric integrin α11β1 on fibroblasts activated actomyosin contractility and matrix remodeling properties. CXCL14-stimulated fibroblasts produced TGFβ and increased osteosarcoma invasion and migration. mAbs targeting the CXCL14-integrin α11β1 axis inhibited fibroblast TGFβ production, enhanced CD8+ T cell–mediated antitumor immunity, and suppressed osteosarcoma lung metastasis. Taken together, these findings identify cross-talk between osteosarcoma cells and fibroblasts that promotes metastasis and demonstrate that targeting the CXCL14-integrin α11β1 axis is a potential strategy to inhibit osteosarcoma lung metastasis.
Significance:
Cooperation between stem-like osteosarcoma cells and fibroblasts mediated by a CXCL14-integrin α11β1 axis creates a tumor-supportive lung metastatic niche and represents a therapeutic target to suppress osteosarcoma metastasis.
Data from Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development
Authors: Goldberg Lior , Haas Eric R. , Urak Ryan , Vyas Vibhuti , Pathak Khyatiben V. , Garcia-Mansfield Krystine , Pirrotte Patrick , Singhal Jyotsana , Figarola James L. , Aldoss Ibrahim , Forman Stephen J. , Wang Xiuli
Published: April 2024

Abstract
Metabolic reprogramming is a hallmark of T-cell activation, and metabolic fitness is fundamental for T-cell–mediated antitumor immunity. Insights into the metabolic plasticity of chimeric antigen receptor (CAR) T cells in patients could help identify approaches to improve their efficacy in treating cancer. Here, we investigated the spatiotemporal immunometabolic adaptation of CD19-targeted CAR T cells using clinical samples from CAR T-cell–treated patients. Context-dependent immunometabolic adaptation of CAR T cells demonstrated the link between their metabolism, activation, differentiation, function, and local microenvironment. Specifically, compared with the peripheral blood, low lipid availability, high IL15, and low TGFβ in the central nervous system microenvironment promoted immunometabolic adaptation of CAR T cells, including upregulation of a lipolytic signature and memory properties. Pharmacologic inhibition of lipolysis in cerebrospinal fluid led to decreased CAR T-cell survival. Furthermore, manufacturing CAR T cells in cerebrospinal fluid enhanced their metabolic fitness and antileukemic activity. Overall, this study elucidates spatiotemporal immunometabolic rewiring of CAR T cells in patients and demonstrates that these adaptations can be exploited to maximize the therapeutic efficacy of CAR T cells.
Significance:
The spatiotemporal immunometabolic landscape of CD19-targeted CAR T cells from patients reveals metabolic adaptations in specific microenvironments that can be exploited to maximize the therapeutic efficacy of CAR T cells.
Supplemental Table 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Authors: Bazinet Alexandre , Desikan Sai Prasad , Li Ziyi , Rodriguez-Sevilla Juan Jose , Venugopal Sangeetha , Urrutia Samuel , Montalban-Bravo Guillermo , Sasaki Koji , Chien Kelly S. , Hammond Danielle , Kanagal-Shamanna Rashmi , Ganan-Gomez Irene , Kadia Tapan M. , Borthakur Gautam , DiNardo Courtney D. , Daver Naval G. , Jabbour Elias J. , Ravandi Farhad , Kantarjian Hagop , Garcia-Manero Guillermo
Published: April 2024

Supplemental Table 2: Variables analyzed in the univariate analysis for associations with overall response rate, overall survival, and event-free survival.
Supplemental Table 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Authors: Bazinet Alexandre , Desikan Sai Prasad , Li Ziyi , Rodriguez-Sevilla Juan Jose , Venugopal Sangeetha , Urrutia Samuel , Montalban-Bravo Guillermo , Sasaki Koji , Chien Kelly S. , Hammond Danielle , Kanagal-Shamanna Rashmi , Ganan-Gomez Irene , Kadia Tapan M. , Borthakur Gautam , DiNardo Courtney D. , Daver Naval G. , Jabbour Elias J. , Ravandi Farhad , Kantarjian Hagop , Garcia-Manero Guillermo
Published: April 2024

Supplemental Table 1: 81-gene next-generation sequencing panel.
Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Authors: Bazinet Alexandre , Desikan Sai Prasad , Li Ziyi , Rodriguez-Sevilla Juan Jose , Venugopal Sangeetha , Urrutia Samuel , Montalban-Bravo Guillermo , Sasaki Koji , Chien Kelly S. , Hammond Danielle , Kanagal-Shamanna Rashmi , Ganan-Gomez Irene , Kadia Tapan M. , Borthakur Gautam , DiNardo Courtney D. , Daver Naval G. , Jabbour Elias J. , Ravandi Farhad , Kantarjian Hagop , Garcia-Manero Guillermo
Published: April 2024

Supplemental Figure 2: Overall survival and event-free survival in HMA-naïve patients with HR-MDS treated with HMA plus venetoclax versus a contemporary cohort treated with HMA monotherapy.
Supplementary Table S2 from Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo
Authors: Read Martin L. , Brookes Katie , Zha Ling , Manivannan Selvambigai , Kim Jana , Kocbiyik Merve , Fletcher Alice , Gorvin Caroline M. , Firth George , Fruhwirth Gilbert O. , Nicola Juan P. , Jhiang Sissy , Ringel Matthew D. , Campbell Moray J. , Sunassee Kavitha , Blower Philip J. , Boelaert Kristien , Nieto Hannah R. , Smith Vicki E. , McCabe Christopher J.
Published: April 2024

Supplementary Table S2
Supplementary Figure S1 from Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo
Authors: Read Martin L. , Brookes Katie , Zha Ling , Manivannan Selvambigai , Kim Jana , Kocbiyik Merve , Fletcher Alice , Gorvin Caroline M. , Firth George , Fruhwirth Gilbert O. , Nicola Juan P. , Jhiang Sissy , Ringel Matthew D. , Campbell Moray J. , Sunassee Kavitha , Blower Philip J. , Boelaert Kristien , Nieto Hannah R. , Smith Vicki E. , McCabe Christopher J.
Published: April 2024

Supplementary Figure S1
Supplementary Table S6 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
Authors: Song Yuqin , Jin Zhengming , Li Zhi-Ming , Liu Yanyan , Li Lanfang , He Chuan , Su Hang , Zhou Hui , Li Kunyan , Hao Siguo , Zuo Xuelan , Wu Jianyuan , Li Dengju , Wu Meng , Sun Xiuhua , Qi Junyuan , Cai Zhen , Li Zengjun , Li Yijing , Huang Yanhua , Shen Jie , Xiao Zhenyu , Zhu Jun
Published: April 2024

Supplementary Table S6. All serious adverse events.
Supplementary Table S1 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Table 1. Rank ordering of the anti-TIP1 antibodies based on their KD values
Supplementary Figure S9 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 9. A. HPLC-SEC analysis of L111 and L111-DFO on an Agilent 1200 series HPLC system using a Zorbax GF-250 9.4 mm ID x 25 cm column (Agilent). DFO conjugation did not change the retention time of the antibody, and no aggregation was observed. B. iTLC showing the radiochemical purity of the radiolabeled L111 antibody. C. Radio-HPLC confirming the radiolabeling of the L111 antibody with [89Zr]Zr.
Supplementary Figure S8 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 8. DFO-to-L111 ratio (DAR) analysis by native MS. The deconvoluted mass spectra (deconvoluted using Intact Mass, Protein Metrics Inc) show the increasing numbers of DFO (+1 to +8). The respective DARs are shown in red.
Supplementary Figure S5 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 5. ELISA shows the affinity of purified human anti-TIP1 full-length IgG1 to TIP1 protein. Recombinant TIP1 protein was coated on ELISA plates. Three-fold serial dilutions (starting at 20 nM) of the purified human anti-TIP1 full-length IgG1 antibodies were incubated with the protein. Anti-human HRP conjugated antibody was used as the detection antibody along with TMB substrate. Absorbance at 450nm vs concentration is plotted in the graph. The data were fitted using the A. “One-site specific” and B. log(agonist) vs. response -- Variable slope (four parameters) model in GraphPad Prism software. The Kd and EC50 values are shown in the table below each graph.
Supplementary Figure S3 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 3. A. Representative chromatogram showing protein A purification profile of the L111 antibody. B. Representative size exclusion chromatogram in S200 10/300 GL columns of the purified L111 antibody.
Supplementary Figure S1 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 1. Strategy for WashU II phage display library creation. The human antibody repertoires were amplified by PCR from the cDNA of mixed human peripheral blood mononuclear cells and cloned randomly into a phagemid vector. This vector encodes for a 16 aa linker (G4S)3T between the VH and VL domain of the scFv and adds an additional C-terminal 6xHis and Flag tag. First, the VH and VL repertoires were amplified in the first set of PCRs and completed by SfiI/XhoI (VH) or SalI/NotI (VL) restriction sites in the second set of PCRs. The VH repertories were cloned first by electroporation in E. coli TG1 (Lucigen, #60502), followed by cloning of the VLkappa or VL-lambda repertories.
Supplementary Table S2 from Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Authors: Earland Noah , Semenkovich Nicholas P. , Ramirez Ricardo J. , Gerndt Sophie P. , Harris Peter K. , Gu Zhuosheng , Hearn Andrew I. , Inkman Matthew , Szymanski Jeffrey J. , Whitfield Damion , Wahle Benjamin M. , Xu Zhongping , Chen Kevin , Alahi Irfan , Ni Gabris , Chen Andrew , Winckler Wendy , Zhang Jin , Chaudhuri Aadel A. , Zevallos Jose P.
Published: April 2024

Supplementary Table S2. Clinical information on patients with HPV (-) oral cavity cancer, or benign conditions
Supplementary Figures 1 from Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
Authors: Connolly Roisin M. , Wang Victoria , Hyman David M. , Grivas Petros , Mitchell Edith P. , Wright John J. , Sharon Elad , Gray Robert J. , McShane Lisa M. , Rubinstein Larry V. , Patton David R. , Williams P. Mickey , Hamilton Stanley R. , Wang Jue , Wisinski Kari B. , Tricoli James V. , Conley Barbara A. , Harris Lyndsay N. , Arteaga Carlos L. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2024

Supplementary Figures
Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Authors: Kawazoe Akihito , Yamamoto Noboru , Sugimoto Naotoshi , Kawakami Hisato , Oshima Takashi , Yamaguchi Kensei , Hino Kaori , Hirao Motohiro , Kurokawa Yukinori , Kawakami Takeshi , Tsuda Masahiro , Hara Hiroki , Kaname Shota , Matsuoka Daiko , Otake Yohei , Yasuda Keisuke , Takase Takao , Takashima Shuya , Semba Taro , Muro Kei
Published: April 2024

Supplementary Table S2. Previous and posttreatment anticancer therapies
Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Authors: Kawazoe Akihito , Yamamoto Noboru , Sugimoto Naotoshi , Kawakami Hisato , Oshima Takashi , Yamaguchi Kensei , Hino Kaori , Hirao Motohiro , Kurokawa Yukinori , Kawakami Takeshi , Tsuda Masahiro , Hara Hiroki , Kaname Shota , Matsuoka Daiko , Otake Yohei , Yasuda Keisuke , Takase Takao , Takashima Shuya , Semba Taro , Muro Kei
Published: April 2024

Supplementary Fig S1. Patient dosing and responses over time (A) and anticancer medication received during follow-up (B)
Supplementary Table S8 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
Authors: Guan Shaoxing , Chen Xi , Wei Yuru , Wang Fei , Xie Wen , Chen Youhao , Liang Heng , Zhu Xia , Yang Yunpeng , Fang Wenfeng , Huang Yan , Zhao Hongyun , Zhang Xiaoxu , Liu Shu , Zhuang Wei , Huang Min , Wang Xueding , Zhang Li
Published: April 2024

Table S8. The potential functional role of rs3744797 by VannoPortal database.
Supplementary Table S6 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
Authors: Guan Shaoxing , Chen Xi , Wei Yuru , Wang Fei , Xie Wen , Chen Youhao , Liang Heng , Zhu Xia , Yang Yunpeng , Fang Wenfeng , Huang Yan , Zhao Hongyun , Zhang Xiaoxu , Liu Shu , Zhuang Wei , Huang Min , Wang Xueding , Zhang Li
Published: April 2024

Table S6. Log-rank analysis in candidate SNPs.